The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Conatus Pharmaceuticals is optimistic that their developmental drug, CTS-1027, will give people with Hepatitis C a greater chance for beating the virus. In a Phase II Hepatitis C trial for previous non-responders, CTS-1027 is being paired with pegylated interferon and ribavirin.
Continue reading »Thanks to progress made in 2009, triple therapy that improves responses to Hepatitis C treatment will likely be available within the next few years.
Continue reading »By targeting Hepatitis C's core protein, Scripps researchers have detected four promising compounds that could block viral reproduction.
Continue reading »By thinking outside the box, the Denmark-based company Santaris Pharma A/S has developed a drug targeting a specific molecule necessary for Hepatitis C replication. Although a very small trial, SPC3649 demonstrates a significant Hepatitis C viral load decline in primates.
Continue reading »Even though an estimated 170 million people worldwide are infected with Hepatitis C, the current treatment can only help about half of them. However, new research suggests that a common vitamin could greatly increase Hepatitis C treatment's effectiveness.
Continue reading »Scientists from Rockefeller University uncover some insights into the Hepatitis C genome that suggests new avenues for weakening this insidious virus.
Continue reading »A recent study revealed that a therapeutic vaccine combined with a topical immune-enhancing agent initiated an immune response against the Hepatitis C virus.
Continue reading »Learn about a phase II trial, whereby Boceprevir was added to standard Hepatitis C therapy (pegylated interferon and ribavirin) and was twice as effective at eliminating the Hep C virus compared to standard therapy alone.
Continue reading »In just three days of a phase I trial, Idenix's experimental, nucleotide-containing Hepatitis C drug (IDX184) demonstrates excellent safety and antiviral activity.
Continue reading »Recent data from a Phase II trial claims that twice daily dosing of telaprevir cured Hepatitis C in over 80 participants.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
